← All stocks

VERACYTE, INC.

VCYT Net selling
CIK 0001384101 #1647 in the set updated 17 Sep 2026
Bought (120 mo)
$1.05M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$274.05M
$16.85M on a plan · $70.01M straight out of an exercise
Sold at will
$187.20M
77 of 353 sales
Net
−$273.00M
−$186.15M against sales at will

By person

30 insiders · 382 transactions
25.2×

Marc Stapley holds 25.2 times base salary in stock. $17.69M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marc Stapley last reported holding, valued at $40.95, the price Common Stock was last bought or sold at on the open market here, on 14 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
EASTHAM KARIN
Director
$149.91M (30)
−$149.91M
19,497
0.0243%
$798.39K
+10.6%
TREU JESSE I
Director
$26.86M (13)
−$26.86M
1,236,571
1.54%
$50.64M
−56.0%
Anderson Bonnie H
Director
$26.05M (66) scheduled
−$26.05M
396,606
0.4933%
$16.24M
+69.7%
JONES EVAN/ FA
Director
$12.28M (53)
−$12.28M
104,287
0.1297%
$4.27M
−75.1%
Kennedy Giulia C
Chief Scientific & Med Officer
$12.22M (53) scheduled
−$12.22M
65,970
0.0821%
$2.70M
+601.3%
Stapley Marc
Chief Executive Officer
$980.09K (1)
$11.15M (11) scheduled
−$10.17M
432,073
0.5375%
$17.69M
+7,904%
Hall Christopher M
President and COO
$6.66M (15) scheduled
−$6.66M
28,258
0.0352%
$1.16M
Hanna John Walter JR
Chief Commercial Officer
$6.47M (19) scheduled
−$6.47M
73,844
0.0919%
$3.02M
+10.3%
Kennedy Keith
COO / CFO
$4.22M (8) scheduled
−$4.22M
116,858
0.1454%
$4.79M
+1,131%
Chambers Rebecca
Chief Financial Officer
$2.82M (12) scheduled
−$2.82M
166,025
0.2065%
$6.80M
+9,113%
McGuire Annie
EVP, General Counsel
$2.74M (17) scheduled
−$2.74M
131,160
0.1632%
$5.37M
+8,535%
EPSTEIN ROBERT S
Director
$2.07M (6) scheduled
−$2.07M
57,718
0.0718%
$2.36M
Leite John
Global Chief Commercial Off
$1.92M (12) scheduled
−$1.92M
128,344
0.1597%
$5.26M
+209.5%
Wygant Jonathan
VP, Chief Accounting Officer
$1.80M (5) scheduled
−$1.80M
43,226
0.0538%
$1.77M
+174.5%
Febbo Phillip G.
Chief Scientific & Med Officer
$1.79M (7) scheduled
−$1.79M
133,048
0.1655%
$5.45M
GORDON KEVIN K
Director
$1.24M (5) scheduled
−$1.24M
8,720
0.0108%
$357.08K
Cohen Fred E
Director
$1.07M (2)
−$1.07M
10,000
0.0124%
$409.49K
Holstein Jens
Director
$70.39K (1)
$1.04M (9) scheduled
−$967.27K
27,471
0.0342%
$1.12M
Ho Mark
Principal Accounting Officer
$624.38K (1)
−$624.38K
71,728
0.0892%
$2.94M
+199.3%
BISHOP JOHN L
Director
$605.00K (2) scheduled
−$605.00K
33,125
0.0412%
$1.36M
Bhanji Muna
Director
$509.08K (7) scheduled
−$509.08K
42,718
0.0531%
$1.75M
KLEINER PERKINS CAUFIELD & BYERS XII, LLC entity
10% owner
2,801,929
3.49%
$114.74M
−21.1%
Nova Tina Susan
President, CLIA U.S.
76,988
0.0958%
$3.15M
+147.3%
Barr Eliav
Director
56,461
0.0702%
$2.31M
Haas Kevin Richard
Chief Dev and Tech Officer
44,221
0.0550%
$1.81M
Shafer David Brent
Director
31,100
0.0387%
$1.27M
Miller Thomas F.
Director
31,100
0.0387%
$1.27M
Alley Beverly Jane
VP, Corporate Controller
13,000
0.0162%
$532.34K
+73.3%
Erlinger III James H
EVP, General Counsel
7,500
0.0093%
$307.12K
Brooks Julie
EVP, Gen Counsel and Secretary
4,162
0.0052%
$170.43K
+10.0%
Insider
Date
Role
Action
Shares
Price
Amount
Stapley Marc
10 Jun 2022
Chief Executive Officer
Buy
60,000
$16.33
$980.09K
Holstein Jens
3 Jun 2021
Director
Buy
2,000
$35.19
$70.39K
Showing 250 of 382 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 492
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 84
Sales straight out of an exercise 192
Sales at will 77
Transactions with no price 0
Shares from compensation/vesting 7,377,221
Sales filed before the plan box existed 64
History held since 8 Dec 2016